GA
ICPT

Geneva Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Geneva Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,670
Closed -$604K – 819
2016
Q3 		$604K Buy
+3,670
New +$579K 0.01% 433

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Geneva Advisors's ICPT Position: Q4 2016 in Review

Geneva Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 3,670 shares — an estimated $604K sold.

Geneva Advisors first reported a position in ICPT in Q3 2016 and held it in 1 quarter. The position peaked at $604K in Q3 2016. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • Geneva Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Geneva Advisors sold 3,670 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $604K.
  • Geneva Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Geneva Advisors's Intercept Pharmaceuticals, Inc. position peaked at $604K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on Geneva Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.